Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera

IntroductionThe first vaccines approved against SARS-CoV-2, mRNA-1273 and BNT162b2, utilized mRNA platforms. However, little is known about the proteomic markers and pathways associated with host immune responses to mRNA vaccination. In this proof-of-concept study, sera from male and female vaccine...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas E. Hickey, Uma Mudunuri, Heidi A. Hempel, Troy J. Kemp, Nancy V. Roche, Keyur Talsania, Brian A. Sellers, James M. Cherry, Ligia A. Pinto
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
serology
proteomics
SARS-CoV-2
mRNA-1273
BNT162b2
vaccine response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1502458/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1502458/full

Similar Items